1.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-06077, NCT00423852
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20070411, NCT00819169
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDX1401-01, NCT00948961
|
|
4.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 10 to 69
Sponsor: NCI
Protocol IDs: UMN-2006LS032, UMN-MT2005-21, UMN-0608M90586, NCT00432094
|
|
5.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-07044, 07-044, NCT00470366
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NCI
Protocol IDs: FHCRC-07156, 07156, CHNMC-07156, NCT00627601
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1200.26, NCT00748709
|
|
9.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06C.549, NCT00437372
|
|
10.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2007.120, NCT00637390
|
|
11.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARRAY-380-101, NCT00650572
|
|
12.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 00012282, 105821b, 9311-06-R0, NCT00672295
|
|
13.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDX-1307-01, NCT00709462
|
|
14.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2008_501, NCT00749502
|
|
15.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL147-003, NCT00756847
|
|
16.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: HBS601, NCT00765973
|
|
17.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 100
Sponsor: NCI
Protocol IDs: NCI-09-C-0019, 09-C-0019, 8054, NCT00792545
|
|
18.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MI-CP177, NCT00796055
|
|
19.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ATDTRPST0802, NCT00800345
|
|
20.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NYU 05-409, NCT00821652
|
|
21.
|
Phase: No phase specified
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TAMC 3H04, NCT00160472
|
|
22.
|
Phase: No phase specified
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2003-0962, NCT00415675
|
|
23.
|
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-08-C-0035, 08-C-0035, NCT00658424
|
|
24.
|
Phase: No phase specified
Type: Health services research, Treatment
Status: Active
Age: 21 and over
Sponsor: Other
Protocol IDs: 08-092, NCT00746018
|
|
25.
|
Phase: No phase specified
Type: Health services research, Natural history/Epidemiology, Supportive care, Treatment
Status: Active
Age: Over 18
Sponsor: NCI
Protocol IDs: CHNMC-07007, 07007, NCT00804258
|
